Table 3. Clinical variables at baseline and at 12 weeks in the mangiferin supplementation and placebo groups.
| Variable |
Placebo group (n = 50) |
Mangiferin group (n = 47) |
P | ||
|---|---|---|---|---|---|
| Baseline | End of intervention | Baseline | End of intervention | ||
| Mangiferin (ng/mL) | 9.11 ± 0.75 | 10.02 ± 0.89 | 9.97 ± 1.03 | 14.15 ± 2.98 | 0.001 |
| TC (mmol/L) | 6.66 ± 0.74 | 6.55 ± 0.86 | 6.62 ± 0.67 | 6.32 ± 0.65 | 0.132 |
| TG (mmol/L) | 2.06 ± 0.26 | 2.01 ± 0.27 | 2.05 ± 0.23 | 1.72 ± 0.19 | 0.001 |
| HDL cholesterol (mmol/L) | 1.27 ± 0.12 | 1.29 ± 0.11 | 1.26 ± 0.13 | 1.35 ± 0.15 | 0.029 |
| LDL cholesterol (mmol/L) | 2.98 ± 0.38 | 2.93 ± 0.35 | 3.02 ± 0.45 | 2.85 ± 0.41 | 0.303 |
| LPL (U/L) | 681.3 ± 132.5 | 695.1 ± 147.6 | 703.4 ± 127.4 | 753.5 ± 122.7 | 0.037 |
| Glucose (mmol/L) | 5.92 ± 1.63 | 5.89 ± 1.61 | 6.01 ± 1.67 | 5.52 ± 1.52 | 0.248 |
| Insulin (μU/mL) | 9.12 ± 4.62 | 9.34 ± 4.96 | 9.21 ± 4.75 | 8.42 ± 4.13 | 0.325 |
| HOMA-IR | 2.61 ± 1.06 | 2.65 ± 1.03 | 2.69 ± 1.12 | 2.25 ± 1.01 | 0.046 |
| L-carnitine (μmol/L) | 24.32 ± 5.64 | 24.92 ± 6.05 | 23.14 ± 5.26 | 27.67 ± 6.12 | 0.028 |
| β-hydroxybutyrate (μmol/L) | 85.15 ± 14.91 | 93.06 ± 14.31 | 89.14 ± 16.87 | 109.51 ± 16.44 | 0.001 |
| Acetoacetate (μmol/L) | 45.51 ± 15.72 | 43.16 ± 15.84 | 45.32 ± 17.37 | 50.27 ± 15.66 | 0.028 |
P values were calculated for the differences between the placebo and mangiferin groups at 12 weeks. The effects of the mangiferin intervention on these variables were analyzed by ANCOVA, with the baseline values of serum mangiferin, age, gender, BMI, blood pressure, dietary intake, hyperlipidemia duration, and drug treatment used as covariates.